Summary & Overview
HCPCS Level II Q4411: Amniomatrix per Square Centimeter (Add-on)
HCPCS Level II code Q4411 designates an amniotic-derived biologic matrix product charged per square centimeter as an add-on item to a primary procedure. These products are used to support wound healing and tissue repair in settings where biologic matrices are applied to surgical sites or chronic wounds. Nationally, add-on supply codes like Q4411 matter because they affect billing accuracy, coverage determinations, and cost transparency for high-cost biologic materials.
Major national payers included in this review are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines which payers commonly cover biologic matrix products, variations in coverage policy language, and how add-on reporting practices influence claim adjudication.
Readers will learn practical benchmarks for utilization and billing of an amniotic matrix product, common policy considerations from major payers, and the clinical context supporting use in wound care and outpatient surgical settings. The summary covers coding placement as an add-on supply, typical sites of service, and the implications for documentation and primary procedure linkage. Data not available in the input is identified where payer-specific coverage details or related codes are not provided.
Billing Code Overview
HCPCS Level II code Q4411 describes Amniomatrixf4x, billed per square centimeter, an add-on supply intended to be reported in addition to a primary procedure. The description indicates the code represents a biologic matrix product derived from amniotic tissue for use in wound care or surgical applications.
Service Type: Biologic graft/supplemental wound care product
Typical Site of Service: Outpatient wound care clinics, ambulatory surgical centers, and hospital outpatient departments
Clinical & Coding Specifications
Clinical Context
A middle-aged adult patient presents to an outpatient wound care or surgical clinic with a chronic non-healing lower extremity wound following diabetic ulceration or traumatic soft-tissue loss. After standard wound bed preparation (debridement, control of infection, optimization of perfusion and glycemic control) the treating clinician elects to apply an amniotic membrane/derived biologic product to promote healing. The product described by Q4411 is billed per square centimeter as an add-on material charge in addition to the primary procedure. Typical clinical workflow: initial wound assessment and documentation of wound size and depth, bedside sharp or surgical debridement, measurement of the treatment area in square centimeters, application of the amniotic matrix product to the prepared wound bed, fixation with appropriate dressings or secondary closure as indicated, and scheduled follow-up visits for dressing changes and reassessment. Typical sites of service include outpatient wound care centers, hospital outpatient departments, ambulatory surgical centers, and office-based procedure suites. Common patient scenarios include diabetic foot ulcers, venous stasis ulcers, surgical graft/closure adjuncts, and complex soft-tissue defects where biologic matrix is used to augment healing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | When another distinct procedure or service was performed on the same day and not normally reported together with the primary procedure applying this add-on material |